Volume 16, Number 9—September 2010
CME ACTIVITY - Research
Illicit Drug Use and Risk for USA300 Methicillin-Resistant Staphylococcus aureus Infections with Bacteremia
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at http://cme.medscape.com/viewpublication/30063; (4) view/print certificate.
Upon completion of this activity, participants will be able to:
- Examine the association of illicit drug use with USA300 MRSA infection, including risk factors for acquisition and transmission.
- Describe characteristics of illicit drug users who acquire MRSA and the changing pattern of risk from 2004 to 2008 in the United States with implications for management and prevention.
Medscape CME Editor
Carol Snarey, MA, Copyeditor, Emerging Infectious Diseases. Disclosure: Carol Snarey has disclosed no relevant financial relationships.
Medscape CME Author
Desiree Lie, MD, MSED, Clinical Professor of Family Medicine, Director of Research and Faculty Development, University of California, Irvine at Orange, California. Disclosure: D&eactue;sir&eactue;e Lie, MD, MSEd, has disclosed the following relevant financial relationship: served as a nonproduct speaker for "Topics in Health" for Merck Speaker Services.
Disclosures: Disclosures: Kristen M. Kreisel, PhD; O. Colin Stine, PhD; Michelle D. Shardell, PhD; Alan J. Lesse, MD; Fred M. Gordin, MD; and Mary-Claire Roghmann, MD, MS, have disclosed no relevant financial relationships. J. Kristie Johnson, PhD, has disclosed the following relationships: received grants for clinical research from Becton, Dickinson and Company. Eli N. Perencevich, MD, MS, has disclosed the following relationships: received grants for clinical support from Pfizer Inc. Michael W. Climo, MD, has disclosed the following relationships: served as an advisor or consultant for Biosynexus Incorporated; received grants for clinical research from Biosynexus Incorporated.
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: August 28, 2011
- Page last updated: August 28, 2011
- Page last reviewed: August 28, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)